{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T08:52:53Z","timestamp":1775638373581,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,3]],"date-time":"2017-09-03T00:00:00Z","timestamp":1504396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Brasileira de Hematologia e Hemoterapia"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.bjhh.2017.08.001","type":"journal-article","created":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T12:30:49Z","timestamp":1505392249000},"page":"325-330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center"],"prefix":"10.1016","volume":"39","author":[{"given":"Jos\u00e9 Carlos","family":"Jaime-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen Magdalena","family":"Gamboa-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Padilla-Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal Alberto","family":"Jim\u00e9nez-Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia Alejandra","family":"Olgu\u00edn-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9sar Homero","family":"Guti\u00e9rrez-Aguirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga Graciela","family":"Cant\u00fa-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"G\u00f3mez-Almaguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bjhh.2017.08.001_bib0150","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdf652","article-title":"Epidemiology and etiology of Hodgkin's lymphoma","volume":"13","author":"Thomas","year":"2002","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bjhh.2017.08.001_bib0155","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.bjhh.2017.08.001_bib0160","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ijc.28049","article-title":"Hodgkin's lymphoma mortality in the Americas, 1997\u20132008: achievements and persistent inadequacies","volume":"133","author":"Chatenoud","year":"2013","journal-title":"Int J Cancer"},{"issue":"17","key":"10.1016\/j.bjhh.2017.08.001_bib0165","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1002\/cncr.30089","article-title":"Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma","volume":"122","author":"Kahn","year":"2016","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.bjhh.2017.08.001_bib0170","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/annonc\/mdr578","article-title":"Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis","volume":"23","author":"Evens","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bjhh.2017.08.001_bib0175","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.seminhematol.2016.05.009","article-title":"Nodular lymphocyte-predominant Hodgkin lymphoma","volume":"53","author":"Savage","year":"2016","journal-title":"Semin Hematol"},{"issue":"32","key":"10.1016\/j.bjhh.2017.08.001_bib0180","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2009.23.3239","article-title":"Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244","volume":"27","author":"Hoskin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bjhh.2017.08.001_bib0185","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(13)70341-3","article-title":"Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis","volume":"14","author":"Skoetz","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9323","key":"10.1016\/j.bjhh.2017.08.001_bib0190","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bjhh.2017.08.001_bib0195","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bjhh.2017.05.003","article-title":"New agents in relapsed\/refractory Hodgkin's lymphoma","volume":"39","author":"Biasoli","year":"2017","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.bjhh.2017.08.001_bib0200","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/968212","article-title":"Clinical options in relapsed or refractory Hodgkin lymphoma: an updated review","volume":"2015","author":"Fedele","year":"2015","journal-title":"J Immunol Res"},{"issue":"4","key":"10.1016\/j.bjhh.2017.08.001_bib0205","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hon.660","article-title":"The new World Health Organization classification of lymphomas: the past, the present and the future","volume":"19","author":"Chan","year":"2001","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.bjhh.2017.08.001_bib0210","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1046\/j.1365-2257.2002.00450.x","article-title":"Role of bone marrow examination in staging Hodgkin's disease: experience in Mexico","volume":"24","author":"Gomez-Almaguer","year":"2002","journal-title":"Clin Lab Haematol"},{"issue":"1","key":"10.1016\/j.bjhh.2017.08.001_bib0215","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/bjh.12878","article-title":"Guidelines for the first line management of classical Hodgkin lymphoma","volume":"166","author":"Follows","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bjhh.2017.08.001_bib0220","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijrobp.2011.11.008","article-title":"Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin's lymphoma with mediastinal involvement","volume":"84","author":"Lu","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.bjhh.2017.08.001_bib0225","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1634\/theoncologist.2014-0218","article-title":"Cost structure and clinical outcome of a stem cell transplantation program in a developing country: the experience in northeast Mexico","volume":"20","author":"Jaime-Perez","year":"2015","journal-title":"Oncologist"},{"issue":"27","key":"10.1016\/j.bjhh.2017.08.001_bib0230","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bjhh.2017.08.001_bib0235","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/ijc.28785","article-title":"Infectious, autoimmune and allergic diseases and risk of Hodgkin lymphoma in children and adolescents: a Children's Oncology Group study","volume":"135","author":"Linabery","year":"2014","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.bjhh.2017.08.001_bib0240","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2613.2001.iep190.x","article-title":"Epstein\u2013Barr virus infection and human malignancies","volume":"82","author":"Niedobitek","year":"2001","journal-title":"Int J Exp Pathol"},{"issue":"8","key":"10.1016\/j.bjhh.2017.08.001_bib0245","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.1988.6.8.1285","article-title":"Third-World Hodgkin's disease at Los Angeles County-University of Southern California Medical Center","volume":"6","author":"Hu","year":"1988","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bjhh.2017.08.001_bib0250","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/1042819031000067729","article-title":"Treatment of advanced Hodgkin's disease: EBVD versus intensive brief chemotherapy","volume":"44","author":"Aviles","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.bjhh.2017.08.001_bib0255","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cam4.655","article-title":"Improved survival time trends in Hodgkin's lymphoma","volume":"5","author":"Koshy","year":"2016","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.bjhh.2017.08.001_bib0260","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3109\/10428194.2011.635861","article-title":"Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series","volume":"53","author":"Guisado-Vasco","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.bjhh.2017.08.001_bib0265","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","article-title":"Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi","volume":"34","author":"Merli","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bjhh.2017.08.001_bib0270","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: a 50-year perspective","volume":"32","author":"Canellos","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bjhh.2017.08.001_bib0275","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.seminhematol.2016.05.010","article-title":"Treatment of relapsed and refractory Hodgkin lymphoma","volume":"53","author":"von Tresckow","year":"2016","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.bjhh.2017.08.001_bib0280","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5581\/1516-8484.20110007","article-title":"Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma","volume":"33","author":"Cortez","year":"2011","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"32","key":"10.1016\/j.bjhh.2017.08.001_bib0285","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1200\/JCO.2007.15.5507","article-title":"Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma","volume":"26","author":"Goodman","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bjhh.2017.08.001_bib0290","first-page":"221","article-title":"New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group","volume":"20","author":"Josting","year":"2002","journal-title":"J Clin Oncol"}],"container-title":["Revista Brasileira de Hematologia e Hemoterapia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1516848417301056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1516848417301056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T12:09:56Z","timestamp":1574856596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1516848417301056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1516848417301056"],"URL":"https:\/\/doi.org\/10.1016\/j.bjhh.2017.08.001","relation":{},"ISSN":["1516-8484"],"issn-type":[{"value":"1516-8484","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center","name":"articletitle","label":"Article Title"},{"value":"Revista Brasileira de Hematologia e Hemoterapia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjhh.2017.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Editora Ltda. on behalf of Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular.","name":"copyright","label":"Copyright"}]}}